TY - JOUR
T1 - A hybrid technique of intracavitary and interstitial brachytherapy for locally advanced cervical cancer
T2 - Initial outcomes of a single-institute experience
AU - Murakami, Naoya
AU - Kobayashi, Kazuma
AU - Shima, Satoshi
AU - Tsuchida, Keisuke
AU - Kashihara, Tairo
AU - Tselis, Nikolaos
AU - Umezawa, Rei
AU - Takahashi, Kana
AU - Inaba, Koji
AU - Ito, Yoshinori
AU - Igaki, Hiroshi
AU - Nakayama, Yuko
AU - Masui, Koji
AU - Yoshida, Ken
AU - Kato, Tomoyasu
AU - Itami, Jun
N1 - Publisher Copyright:
© 2019 The Author(s).
PY - 2019/3/12
Y1 - 2019/3/12
N2 - Background: Locally advanced uterine cervical cancer (LAUCC) with lateral tumor extension may not always be covered adequately by conventional intracavitary brachytherapy (ICBT). Hybrid intracavitary and interstitial brachytherapy (HBT) seems to be an effective alternative by improving anatomy-oriented dose optimisation. The purpose of this study was to report initial clinical result for LAUCC treated by HBT. Methods: Between January 2012 and November 2015, 42 patients with LAUCC (T1b2-4a) were treated with primary radiation therapy including HBT. Patients with distant metastasis other than para-aortic lymph node spread were excluded from this study. A retrospective analysis was performed for toxicity evaluation and oncological outcome calculation. Results: Median follow-up was 23.2 months (range 13.2-71.4). Two-year overall survival, progression free survival, and local control rate were 81.6, 54.4, and 80.2%, respectively. Seven patients experienced local recurrence (16.6%). Of those, five were confined to the uterus and two at the parametria. Late adverse events ≥ grade 3 were seen in 3 patients. Conclusions: HBT can generate favorable local control in tumors which cannot be adequately covered by ICBT.
AB - Background: Locally advanced uterine cervical cancer (LAUCC) with lateral tumor extension may not always be covered adequately by conventional intracavitary brachytherapy (ICBT). Hybrid intracavitary and interstitial brachytherapy (HBT) seems to be an effective alternative by improving anatomy-oriented dose optimisation. The purpose of this study was to report initial clinical result for LAUCC treated by HBT. Methods: Between January 2012 and November 2015, 42 patients with LAUCC (T1b2-4a) were treated with primary radiation therapy including HBT. Patients with distant metastasis other than para-aortic lymph node spread were excluded from this study. A retrospective analysis was performed for toxicity evaluation and oncological outcome calculation. Results: Median follow-up was 23.2 months (range 13.2-71.4). Two-year overall survival, progression free survival, and local control rate were 81.6, 54.4, and 80.2%, respectively. Seven patients experienced local recurrence (16.6%). Of those, five were confined to the uterus and two at the parametria. Late adverse events ≥ grade 3 were seen in 3 patients. Conclusions: HBT can generate favorable local control in tumors which cannot be adequately covered by ICBT.
KW - Brachytherapy
KW - Hybrid of intracavitary and interstitial brachytherapy
KW - Patterns of recurrence
KW - Uterine cervical cancer
UR - http://www.scopus.com/inward/record.url?scp=85062833205&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85062833205&partnerID=8YFLogxK
U2 - 10.1186/s12885-019-5430-x
DO - 10.1186/s12885-019-5430-x
M3 - Article
C2 - 30866877
AN - SCOPUS:85062833205
SN - 1471-2407
VL - 19
JO - BMC Cancer
JF - BMC Cancer
IS - 1
M1 - 221
ER -